INTRODUCTION
Primary percutaneous coronary intervention (pPCI) with stent implantation is acknowledged as the optimal treatment strategy in patients with acute myocardial infarction (AMI) [1] . Primary PCI with bare metal stent (BMS) implantation has been associated with a significant improvement in clinical outcome and therefore has become standard practice [1] . The introduction of drug-eluting stents (DES) has emerged as a rational pPCI alternative in this particular setting of AMI [2] .
Recently, it has been suggested that the type of stent used in pPCI might impact upon the outcomes of patients with AMI [3] . Indeed, DES has been confirmed as reducing neointimal hyperplasia and persistent fibrin deposition compared to BMS [4] . Moreover, the later generation DES, due to its biocompatible polymer coatings and stent design, allows for greater deliverability, improved endothelial healing and therefore less restenosis and reinfarction [5] . However, concerns have been raised with regard to the safety of DES, particularly in the AMI setting [5] [6] [7] . In the recently published COMFORTABLE AMI Trial, a comparison of new-generation biolimus-eluting stents (BES) and BMS resulted in a reduction of a composite of major adverse cardiovascular events among patients with ST-segment-elevation myocardial infarction (STEMI) undergoing pPCI [8] . However, randomised clinical trials (RCTs) did not confirm the benefit of DES as regards the mortality rate [9] . Due to the conflicting reports regarding the hard outcomes after DES vs. BMS implantation, the most accurate treatment strategy of pPCI during AMI is still the subject of debate.
In this context, we performed a post hoc analysis from a prospective, multicentre cohort to investigate whether DES compared to BMS influences early outcomes in the setting of AMI. The presented all-comer observation addresses the real-world setting and therefore reflects the care of patients in routine clinical practice.
METHODS

Study design and population
The Acute Myocardial Infarction in Switzerland (AMIS) Plus project was launched in January 1997 as a large, nationwide prospective registry of patients admitted with acute coronary syndrome (ACS) to 82 hospitals in Switzerland, including STEMI, non-STEMI (NSTEMI) and unstable angina (Fig. 1) . The registry is officially supported by the Swiss Societies of Cardiology, Internal Medicine and Intensive Care Medicine. The design of the registry has been previously described [10, 11] . All participating centres, ranging from community institutions to large tertiary facilities, provide blinded data, being subsequently centralised at the AMIS Plus Data Centre. All data provided through an internet or paper-based questionnaire was subsequently checked for plausibility and consistency in the Institute of Social and Preventive Medicine at the University of Zurich, Switzerland. The registry was approved by the Over-Regional Ethics Committee for Clinical 
Statistical analysis
The results are presented as percentages for categorical variables and analysed using the non-parametric Pearson c 2 test or Fisher's exact test as appropriate. Continuous variables are expressed as means ± standard deviation (SD) and compared using the Student's unpaired t-test for normal distribution and continuous non-normally distributed variables are expressed as median and interquartile ranges and analysed using the Mann-Whitney U test. To examine predictors for in-hospital mortality, multivariate logistic regression was used and included the following variables: stent type (BMS or DES), multi-vessel revascularisation, age, gender, LM involvement, Killip class > 2, Charlson comorbidities weighted index > 2 and out-of-hospital resuscitation. To limit the observational character of the study, we performed a propensity score matching to create matched DES (n = 2,137) and BMS (n = 2,137) cohorts. Optimal matching was obtained using a logistic regression model with stent type used as dependent variable. Independent variables were age, gender, resuscitation before admission, STEMI, Killip class > 2, Charlson comorbidity score ≥ 2 and MVD. All statistical tests were two-tailed. P-value of < 0.05 was considered statistically significant. SPSS software (version 19, SPSS Inc, Chicago, IL, USA) was used for all statistical analyses. Studies, the Swiss Board for Data Security, and all cantonal Ethics Commissions.
Data extraction
The AMIS Plus Central Database collects 230 items including medical history, co-morbidities, known cardiovascular risk factors (dyslipidaemia, arterial hypertension, diabetes, obesity and smoking), clinical presentation, out-of-hospital management, early in-hospital management, reperfusion therapy, hospital course, diagnostic tests used or planned, length of stay, discharge medication and discharge destination, immediate drug treatment and discharge medication. The non-cardiovascular co-morbidities were assessed using the Charlson index [12] . Patients were enrolled in the registry based on their final diagnosis.
Patient selection
Between January 2005 and March 2013, 20,464 patients with AMI (STEMI and NSTEMI) were enrolled to the AMIS Plus registry. 17,651 underwent any pPCI. Of these, 15,026 underwent pPCI and 13,442 pPCI with stent implantation. 10,094 patients were implanted with DES and 2,260 with BMS. 942 patients were excluded from the final analysis due to lack of data regarding the stent type. 146 patients received variable absorbable scaffolds. The study flow chart is presented in Figure 2 .
Definitions STEMI was defined by characteristic symptoms with electrocardiographic (ECG) changes and cardiac marker elevation (creatine kinase MB fraction at least twice the upper limit of normal or troponin I or T above individual hospital cut-off levels for MI). All patients required ST-segment elevation and/or a new development of left bundle branch block (LBBB) on the initial ECG at presentation. NSTEMI was defined as cardiac marker elevation with no ST-elevation in admission ECG.
Reinfarction was defined as clinical signs or symptoms of ischaemia with ECG changes indicative of new ischaemia (new ST-changes or new LBBB) and a re-rise of biomarkers following the initial infarction. A cerebrovascular event was defined as any event due to ischaemic, thrombotic or haemorrhagic disturbances confirmed by a neurologist or imaging modality.
Multivessel disease (MVD) was defined as a presence of angiographic stenosis of ≥ 50% in at least two main epicardial coronary arteries and/or involving the left main (LM) when a surgical bypass graft was concerned. The decision regarding single-vessel PCI (S-PCI) or multivessel PCI (M-PCI) attempt and DES or BMS implantation was performed at the physician's discretion.
Study endpoints
The primary endpoint of the study was in-hospital all-cause mortality. Secondary endpoints included a composite endpoint of major adverse cardiac and cerebrovascular events (MACCE) including death, reinfarction and/or cerebrovascular event. 
RESULTS
Study population and baseline
Of the included 12,354 patients undergoing the pPCI and stent implantation during AMI between 2005 and 2013, we identified 10,094 (82%) patients with DES and 2,260 (18%) patients with BMS implantation (Fig. 2) . Baseline characteristics, stratified by stent use, are shown in Table 1 IQR 99-450, p = 0.082). In general, rates of BMS implantation were greater among sicker patients with a history of out-of-hospital reanimation, Killip class III/IV, cerebrovascular disease, renal disease, cancer, and Charlson weighted index ≥ 2. A DES was more likely used in patients with LM stenosis and MVD. In addition, immediate drug therapy with acetylsalicylic acid, glycoprotein IIb/IIIa inhibitors, beta-blockers and angiotensin-converting-enzyme inhibitors/angiotensin II receptor antagonists and statins were more prevalent in patients treated with BMS. In contrast, vasopressors were more frequently used among patients receiving DES compared to BMS. No difference was noted in terms of P2Y12 blockers use between the two groups ( Table 2) .
In-hospital outcomes and predictors of mortality
Overall, in-hospital mortality after DES implantation was lower compared to BMS (2.6% vs. 7.1%, p < 0.001), as was MACCE (3.5% vs. 7.6%, p < 0.001, Table 3 ).
After adjusting for all different covariables, a DES remained a positive independent predictor of survival (odds ratio [OR] 0.51, 95% confidence interval [CI] 0.40-0.67, p < 0.001, Table 4 ). In multivariable regression, STEMI, MVD, LM lesion, age, Charlson weighted index ≥ 2, out-of-hospital cardiac arrest and Killip III/IV were also identified as predictors of in-hospital mortality (Table 4) . No differences were noted in the rate of reinfarction and cerebrovascular events (Table 3 ). An additional analysis regarding the cardiogenic shock after the pPCI and bleeding rate did not show any differences between the two groups receiving DES or BMS (Table 3) . Propensity score matching (2,137 DES vs. 2,137 BMS) Even after propensity score matching, significant reductions in mortality rate and overall MACCE were noted in patients receiving DES compared to BMS (3.8% vs. 5.8%, p = 0.004; 4.8% vs. 6.4%, p = 0.033, respectively). DES implantation remained independently associated with a reduced risk of in-hospital mortality (adjusted OR 0.54, 95% CI 0.39-0.76, p < 0.001).
DISCUSSION
Our results suggest that DES is beneficial compared to BMS regarding in-hospital mortality and overall MACCE. This observational analysis includes a real-world population and therefore reflects routine clinical practice.
DES has been proven more effective than BMS in preventing the need for repeat revascularisation [13] [14] [15] . The restenosis rate of nearly 20% to 30% within 6-9 months BMS -bare-metal stent; CI -confidence interval; DES -drug-eluting stent; MI -myocardial infarction after BMS implantation has often been called the Achilles heel of pPCI [16] . The introduction of DES correlated with reduced angiographic restenosis and ischaemia-driven target vessel revascularisation rates has substantially strengthened the efforts to improve the success rate over the last decades [17, 18] . Restenosis remains the healing response to wire-, balloon-and stent-induced injury and comprises neointimal hyperplasia and vessel remodelling. Although the reduction of restenosis rate relates rather to mid-term follow-up, the immediate release of drugs (80-90% eluted within 30 days) can rapidly reduce late loss by targeting cell cycle division also early after stent implantation [19] . However, despite the reduction in reintervention rates, no robust clinically relevant differences up to five-year follow-up have been convincingly identified [16] . The results abstracted from RCTs revealed no significant differences as regards long-term rates of death or MI after DES or BMS use for both off-label and on-label indications [17, 20, 21] . However, the RCTs were primarily limited by population-size. Only the observational studies, with greater numbers of patients, have presented DES use as a better treatment strategy compared to BMS associated with reduced death and MI [20] . Importantly, the recently published RCTs suggest that the new-generation DES may provide superior clinical outcomes to first-generation DES in patients with coronary artery disease and in real-world practice [22, 23] . The differences are driven in part by in-hospital MI and early in-stent thrombosis [24] . A major matter of debate is DES implantation during the pPCI in patients with AMI [16] . Our analysis, based on an unselected AMI subset and reflecting the real-world population, documented an improved adverse outcome measure and all-cause death with a similar rate of reinfarction. Some previous studies have been similarly in favour of DES (i.e. TYPHOON, HORIZONS-AMI, PASEO, and ZEST-AMI), whereas others have presented opposite results [7, 16, 25, 26] . In the PASEO study, sirolimus-eluting stents (SES) and paclitaxel-eluting stents were documented to be safe and effective compared to BMS, with similar overall mortality [27] . Mauri et al. [28] in their propensity-score-matched group documented that risk-adjusted mortality rates and repeat revascularisation were lower for DES than for BMS among all patients with AMI, including both STEMI and NSTEMI, STEMI alone, and NSTEMI alone. Reinfarction was reduced after DES implantation compared to BMS in the NSTEMI subset [28] . On the other hand, the PASSION trial did not reveal any benefit after DES implantation compared to BMS in terms of clinical outcomes after one-and five-year observations [29, 30] . Kaltoft et al. [7] reported 12 deaths before discharge and four classified as probable stent thrombosis in patients implanted with DES, and four deaths after BMS implantation including only one possible in-stent thrombosis. The early and late in-stent thrombosis could be caused by e.g. local allergic reactions, inflammation, and delayed endothelialisation of the first-generation DES [31] . Meanwhile, newly-engineered DES have been developed with thinner-strut platforms made of improved alloys providing increased radial strength and radiopacity [5] . This may result in less vascular injury and therefore reduced restenosis and throbogenicity [5, 32] . The EXAMI-NATION trial comparing everolimus-eluting stents (EES) with BMS in a group of STEMI did not reveal any patient-oriented benefit of EES use [33] as regards the risk of restenosis and in-stent thrombosis [33] . The recently published COMFORT-ABLE trial presented that the newly-designed biodegradable polymer BES reduce adverse outcomes compared to BMS mostly due to a significant reduction in rates of reinfarction and reintervention [34] . Also, fewer cases of definite in-stent thrombosis were observed in the group of BES compared to BMS, although the difference was not significant [34] . The use of biodegradable polymers in newly-engineered DES offers early protection against in-stent thrombosis avoiding its very late proinflammatory and prothrombotic effect [32, 35] . Therefore, concerns regarding the late safety issue with DES are rather related to early-designed DES [8, 36] . New DES have replaced the early-generation DES in clinical practice, and, what is more, the old-fashioned SES such as CYPHER are no longer manufactured [5] . Nowadays, use of DES in AMI has a class IIA recommendation if patients are able to comply with a prolonged regimen of dual antiplatelet therapy [16] .
Limitations of the study
The major limitation of the presented study is its observational nature with potential for selection bias and residual confounding. Thus, patients with AMI who receive DES may be less ill than those who receive BMS; our analysis attempted to adjust for these differences to the extent that was possible. Second, the study was underpowered to reveal late in-stent thrombosis which remains the major limitation of early-generation DES. Third, the use of stent type was at the discretion of the operator and no data regarding the use of thrombectomy is available. The number of stents was not systematically recorded and therefore an additional analysis of cases with mixed stents was not possible. Moreover, our database did not allow us to distinguish the particular stent type implanted; therefore, other aspects of the stent design (e.g. strut size and thickness, stent material, drug or polymer) and its influence on outcome remains unknown. The present analysis addresses, however, all consecutive patients referred for urgent pPCI due to ACS and reflects real-world practice. Moreover, since our patients were not randomly assigned, we performed a propensity score matching to limit the potential biases.
CONCLUSIONS
The use of DES in patients with AMI undergoing pPCI appears to be associated with improved mortality and overall in-hospital adverse outcomes compared to BMS. The promising results of the present analysis warrant discussion, and therefore call for an extended follow-up and perhaps larger randomised controlled trials to examine this strategy in real-world populations.
